Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.

by Tomonaga Ichikawa, Jinqing Li, Colin J Meyer, Joseph S Janicki, Mark Hannink, Taixing Cui
Published 2009-01-01

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease

by Mohammad A. Aminzadeh, Scott A. Reisman, Nosratola D. Vaziri, Stan Shelkovnikov, Seyed H. Farzaneh, Mahyar Khazaeli, Colin J. Meyer
Published 2013-01-01

Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.

by Yifan Xing, Ting Niu, Wenjuan Wang, Jinqing Li, Siying Li, Joseph S Janicki, Stacey Ruiz, Colin J Meyer, Xing Li Wang, Dongqi Tang, Yuxia Zhao, Taixing Cui
Published 2012-01-01

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD

by James H. Lewis, Michel Jadoul, Geoffrey A. Block, Melanie P. Chin, Deborah A. Ferguson, Angie Goldsberry, Colin J. Meyer, Megan O’Grady, Pablo E. Pergola, Scott A. Reisman, W. Christian Wigley, Glenn M. Chertow
Published 2021-01-01